D.Western Therapeutics Institute AI Stock Analysis
Want to see JP:4576 full AI Analyst Report?
D.Western Therapeutics Institute (4576) AI Stock Analysis
D.Western Therapeutics Institute
(TSE/TYO:4576)
Primarily driven by weak financial performance with persistent losses and negative cash flows, followed by bearish technical indicators showing price action below key moving averages and negative MACD; valuation is limited by negative earnings.
D.Western Therapeutics Institute (4576) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 2.93B
- Dividend Yield
- ―
- Average Volume (3M)
- 351.51K
- Price to Earnings (P/E)
- -4.3
- Beta (1Y)
- 0.04
- Revenue Growth
- -41.25%
- EPS Growth
- 55.11%
- Country
- Japan
- Employees
- 19
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
D.Western Therapeutics Institute Business Overview & Revenue Model
Company Description
D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutions prescribed...
D.Western Therapeutics Institute Financial Statement Overview
Summary
Persistent net losses, revenue decline of 7.9%, and deeply negative operating cash flow (-493.8M) overshadow high gross margins and recent debt-to-equity improvement to 0.42.
Income Statement
25NegativeBalance Sheet
45NeutralCash Flow
20Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 305.74M | 387.62M | 471.58M | 428.36M | 448.10M | 414.42M |
| Gross Profit | 251.40M | 301.24M | 424.74M | 391.70M | 420.53M | 394.32M |
| EBITDA | -611.09M | -572.35M | -1.23B | -775.59M | -390.75M | -110.03M |
| Net Income | -651.85M | -632.09M | -1.29B | -812.41M | -429.69M | -149.00M |
Balance Sheet | ||||||
| Total Assets | 1.97B | 2.17B | 1.67B | 2.37B | 2.96B | 2.46B |
| Cash, Cash Equivalents and Short-Term Investments | 1.54B | 1.71B | 1.13B | 1.87B | 2.33B | 1.93B |
| Total Debt | 594.17M | 605.18M | 797.98M | 885.12M | 967.69M | 340.00M |
| Total Liabilities | 654.26M | 734.01M | 935.57M | 1.09B | 1.08B | 427.72M |
| Stockholders Equity | 1.31B | 1.44B | 733.87M | 1.28B | 1.86B | 2.01B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -496.54M | -1.31B | -601.76M | -364.58M | -179.21M |
| Operating Cash Flow | 0 | -493.79M | -1.30B | -586.82M | -354.77M | -176.31M |
| Investing Cash Flow | 0 | -2.45M | -10.01M | -15.25M | -139.89M | -111.15M |
| Financing Cash Flow | 0 | 1.08B | 567.63M | 134.47M | 867.30M | -104.46M |
D.Western Therapeutics Institute Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4576, the sentiment is Negative. The current price of 51.00 is below the 20-day moving average (MA) of 60.50, below the 50-day MA of 71.20, and below the 200-day MA of 83.41, indicating a bearish trend. The MACD of -5.83 indicates Positive momentum. The RSI at 19.35 is Positive, neither overbought nor oversold. The STOCH value of 16.03 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4576.
D.Western Therapeutics Institute Peers Comparison
Overall Rating
JP:459349Neutral
JP:497843Neutral- JP:457639Underperform
JP:459239Underperform
JP:459938Underperform
JP:777626Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4593 | 49Neutral | JPY 32.26B | 48.59 | ― | ― | -47.32% | ― |
| JP:4978 | 43Neutral | JPY 11.97B | -24.40 | ― | ― | -18.71% | -246.54% |
| JP:4576 | 39Underperform | JPY 2.93B | -4.29 | -45.41% | ― | -41.25% | 55.11% |
| JP:4592 | 39Underperform | JPY 67.21B | -17.98 | -37.79% | ― | ― | 5.71% |
| JP:4599 | 38Underperform | JPY 7.46B | -4.04 | ― | ― | ― | 4.85% |
| JP:7776 | 26Underperform | JPY 6.90B | -5.90 | ― | ― | -56.16% | 3.12% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4576 | D.Western Therapeutics Institute, Inc. | 51.00 | -53.00 | -50.96% | |
| JP:4592 | SanBio Co | 862.00 | -1766.00 | -67.20% | |
| JP:4593 | Healios KK | 241.00 | -220.00 | -47.72% | |
| JP:4599 | StemRIM Inc. | 119.00 | -168.00 | -58.54% | |
| JP:4978 | ReproCELL Inc. | 115.00 | -53.00 | -31.55% | |
| JP:7776 | CellSeed Inc. | 171.00 | -261.00 | -60.42% |
D.Western Therapeutics Institute Corporate Events
D. Western Therapeutics Outlines Q2 FY12/26 Results and Outlook
D. Western Therapeutics Institute has released briefing materials for its second quarter results for the fiscal year ending December 2026. The documents outline financial performance, progress in business activities, and an updated forecast for the f...
D.Western Therapeutics Posts Deeper Losses, Keeps 2026 Outlook Unchanged
D.Western Therapeutics Institute reported consolidated net sales of ¥33 million for the first half of 2026, an 80.9% year-on-year decline, with an operating loss of ¥312 million and a net loss attributable to owners of the parent of ¥323 million. Des...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026